logo
Plus   Neg
Share
Email

BioNTech, Fosun Pharma Begin Clinical Trial Of MRNA-based COVID-19 Vaccine Candidate In China

BioNTech SE (BNTX) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd announced Wednesday that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA).

The Phase 1 trial will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in China.

The randomized, placebo-controlled, observer-blinded Phase 1 clinical trial in China will enroll 144 healthy subjects to evaluate the safety and immunogenicity of the vaccine as well as to confirm dose selection. Trial participants will receive either 10µg or 30µg of BNT162 or a placebo.

BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.

BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech's global development program aimed at supporting a global supply upon regulatory approval.

The ongoing clinical studies conducted in Germany and the United States will continue to support studies in China.

The companies also intend to explore the possibility of initiating clinical development of other vaccine candidates based on BioNTech's proprietary mRNA technology in China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT